Travere Therapeutics, Inc.·4

May 12, 8:33 PM ET

Poole Sandra 4

4 · Travere Therapeutics, Inc. · Filed May 12, 2022

Insider Transaction Report

Form 4
Period: 2022-05-11
Poole Sandra
Director
Transactions
  • Award

    Common Stock

    2022-05-11+3,00012,500 total
  • Award

    Stock option (right to buy)

    2022-05-11+9,0009,000 total
    Exercise: $21.38From: 2023-05-11Exp: 2032-05-10Common Stock (9,000 underlying)
Footnotes (2)
  • [F1]Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.
  • [F2]The equity award vests over a one year period.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION